ORGS Orgenesis Inc

Price (delayed)

$0.822

Market cap

$26.2M

P/E Ratio

0.91

Dividend/share

N/A

EPS

$0.9

Enterprise value

$47.16M

Orgenesis is a global biotech company working to unlock the full potential of cell and gene therapies (CGTs) in an affordable and accessible format at the point of care. The ...

Highlights
The EPS has surged by 73% since the previous quarter and by 43% year-on-year
The price to earnings (P/E) is 59% less than the last 4 quarters average of 2.2
Orgenesis's debt has decreased by 24% YoY but it has increased by 5% QoQ
The company's net income has shrunk by 82% QoQ and by 59% YoY
The quick ratio has plunged by 63% YoY and by 15% from the previous quarter

Key stats

What are the main financial stats of ORGS
Market
Shares outstanding
31.88M
Market cap
$26.2M
Enterprise value
$47.16M
Valuations
Price to earnings (P/E)
0.91
Price to book (P/B)
1.89
Price to sales (P/S)
0.86
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.7
Earnings
Revenue
$27.75M
EBIT
-$22.2M
EBITDA
-$20.32M
Free cash flow
-$32.46M
Per share
EPS
$0.9
Free cash flow per share
-$1.11
Book value per share
$0.44
Revenue per share
$0.95
TBVPS
$1.17
Balance sheet
Total assets
$45.3M
Total liabilities
$32.9M
Debt
$21.75M
Equity
$12.4M
Working capital
-$5.53M
Liquidity
Debt to equity
1.75
Current ratio
0.61
Quick ratio
0.33
Net debt/EBITDA
-1.03
Margins
EBITDA margin
-73.2%
Gross margin
28.5%
Net margin
-90.3%
Operating margin
-33.9%
Efficiency
Return on assets
-35.3%
Return on equity
-109.5%
Return on invested capital
-36.6%
Return on capital employed
-71.6%
Return on sales
-80%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ORGS stock price

How has the Orgenesis stock price performed over time
Intraday
-3.29%
1 week
-5.52%
1 month
31.94%
1 year
-37.25%
YTD
64.17%
QTD
64.17%

Financial performance

How have Orgenesis's revenue and profit performed over time
Revenue
$27.75M
Gross profit
$7.91M
Operating income
-$9.4M
Net income
-$25.07M
Gross margin
28.5%
Net margin
-90.3%
Orgenesis's net margin has shrunk by 134% QoQ and by 67% YoY
The company's net income has shrunk by 82% QoQ and by 59% YoY
The operating margin has dropped by 69% since the previous quarter but it is up by 33% year-on-year
The operating income has increased by 37% year-on-year but it has declined by 31% since the previous quarter

Growth

What is Orgenesis's growth rate over time

Valuation

What is Orgenesis stock price valuation
P/E
0.91
P/B
1.89
P/S
0.86
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.7
The EPS has surged by 73% since the previous quarter and by 43% year-on-year
The price to earnings (P/E) is 59% less than the last 4 quarters average of 2.2
Orgenesis's equity has shrunk by 59% YoY and by 48% QoQ
ORGS's P/B is 35% below its 5-year quarterly average of 2.9 but 26% above its last 4 quarters average of 1.5
ORGS's price to sales (P/S) is 88% less than its 5-year quarterly average of 7.1 and 14% less than its last 4 quarters average of 1.0
ORGS's revenue is down by 22% since the previous quarter and by 5% year-on-year

Efficiency

How efficient is Orgenesis business performance
The return on sales has dropped by 167% since the previous quarter and by 68% year-on-year
The company's return on equity has shrunk by 134% YoY and by 118% QoQ
The return on invested capital has dropped by 109% since the previous quarter
Orgenesis's ROA has plunged by 98% from the previous quarter and by 41% YoY

Dividends

What is ORGS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ORGS.

Financial health

How did Orgenesis financials performed over time
ORGS's total assets is 38% higher than its total liabilities
The quick ratio has plunged by 63% YoY and by 15% from the previous quarter
ORGS's total assets is down by 36% YoY and by 17% QoQ
Orgenesis's debt is 75% higher than its equity
Orgenesis's debt to equity has surged by 103% QoQ and by 84% YoY
Orgenesis's equity has shrunk by 59% YoY and by 48% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.